Xiangyu Gao, Ke Ji, Yongning Jia, Fei Shan, Ye Chen, Nong Xu, Ziyu Jia, Tianshu Liu, Nong Yang, Haijun Zhong, Changzheng Li, Zengqing Guo, Qingxia Fan, Xiaoyan Lin, Yan Zhang, Hui Ren, Hongxia Yang, Zhifang Yao, Wei Liu, Zhongmin Maxwell Wang, Baiyong Li, Michelle Xia, Lin Shen, Ziyu Li, Jiafu Ji
Treatment with anti-programmed cell death protein 1 (PD-1) therapy and chemotherapy prolongs the survival of patients with unresectable advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma. The benefit from anti-PD-1 therapy is enriched in patients with programmed cell death 1 ligand 1 (PD-L1) combined positive score (CPS)-positive or CPS-high tumors compared with patients with PD-L1 CPS-negative or CPS-low tumors. In this phase 1b/2 study, we evaluated the efficacy and safety of cadonilimab, a bispecific antibody targeting PD-1 and cytotoxic T-lymphocyte antigen-4, plus chemotherapy as first-line treatment in patients with human epidermal growth factor receptor 2-negative unresectable advanced or metastatic gastric or GEJ adenocarcinoma...
May 22, 2024: Nature Medicine